If there is one common problem that residents in the United States are consistently faced with, it is suffering from some form of asthma or an asthma-like illness. Currently, the Centers for Disease Control and Prevention (often recognized as the C.D.C.), has estimated that nearly 20.3 million people are suffering from a condition similar to the aforementioned. Additionally, nearly 33 million individuals have been diagnosed with a form of asthma during their lives.
Asthma is not the only widespread concern though, as the nationwide prevalence of emphysema and chronic bronchitis has recently reached an estimated total of around 16 million individuals. Of the sixteen million estimated cases, nearly fourteen million cases were due to chronic bronchitis and two million from emphysema. In retrospect of this data, it can be broadly estimated that the entire United States-based pulmonary disease market reaches enormous totals climaxing at around thirty million people. For this very reason, EmphyCorp's a brand of discovery pharmaceutical technology will thrive and absolutely flourish.
EmphyCorp has the resources, the will power and most of all, the necessary proprietary technology to take the next step of penetrating this market and securing a substantial major market share. Through an introductory approach, EmphyCorp is going to target the United States pulmonary disease market, a substantial portion of individuals that reaches nearly thirty million. Once the American market has been successfully targeted, the company will move to worldwide markets by entering numerous sublicensing agreements, joint ventures or outright sale with respiratory drug companies and manufacturers seeking to entire the pharmaceutical market.
As one of the most innovative and newly-acclaimed pharmaceutical companies, EmphyCorp is set to become one of the industry's most exclusive up-and-coming companies. With numerous patents filed and issued, the company is set to make strides towards greatness in helping the major market of pulmonary diseases. By addressing this concern, EmphyCorp is taking aim at pulmonary disease patients one at a time.